Lead Compound - Scientific Publications

Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.

de Maat, S., Clark, C. C., Barendrecht, A. D., Smits, S., van Kleef, N. D., el Otmani, H., Waning, M., van Moorsel, M., Szardenings, M., Delaroque, N., Vercruysse, K., Urbanus, R. T., Sebastian, S., Lenting, P. J., Hagemeyer, C., Renné, T., Vanhoorelbeke, K., Tersteeg, C., & Maas, C. (2022). Blood, The Journal of the American Society of Hematology, 139(4), pp.597-607.

VWF-targeted thrombolysis to overcome rh-tPA resistance in experimental murine ischemic stroke models.

van Moorsel, M. V. A., de Maat, S., Vercruysse, K., van Leeuwen, E. M., Jacqmarcq, C., Bonnard, T., Vivien, D., van der Worp, H. B., Dijkhuizen, R. M., & Maas, C. (2022). Blood, The Journal of the American Society of Hematology, 140(26), pp.2844-2848.

TGD001, a VWF-targeted thrombolytic, is safe and effective in animal models for the treatment of thrombotic thrombocytopenic purpura.

C. Tersteeg¹, S. Mc Fie², D. Versluis², A. Delmote¹, K. Vercruysse², K. Wosikowski², G. van ‘t Klooster², K. Vanhoorelbeke¹, S. de Maat².
¹KU Leuven Campus Kulak, Kortrijk, Belgium
²TargED Biopharmaceuticals B.V., Utrecht, the Netherlands